动态血糖检测评估诺和锐30与诺和灵30R治疗2型糖尿病的血糖波动和低血糖事件

Dynamic glucose monitoring assessment on BIAsp30 and BHI30 for treating glycemic excursion and hypoglycemic events in type 2 diabetes mellitus

目的探讨预混门冬氨酸30(诺和锐30)与预混人胰岛素(诺和灵30 R)在治疗2型糖尿病患者中血糖事件波动和低血糖发生情况的差异。方法将口服降糖药控制不佳的患者随机分为诺和锐30组与诺和灵30 R组,待指血糖达标后用动态血糖仪监测3 d,观察两组血糖波动和低血糖事件发生情况。结果两组患者平均指血糖和指血糖的最高、最低值比较,差异无统计学意义(P>0.05),但是用连续血糖检测系统(CGMS)监测发现诺和锐30组血糖波动和低血糖事件比诺和灵30 R组明显减少,差异有统计学意义(P<0.05)。结论在2型糖尿病患者中诺和锐30虽然控制血糖的能力与诺和灵30 R相当,但是具有更少的血糖波动和低血糖事件;因此,在2型糖尿病治疗中依然有一定的优势,值得推广应用。

Objective To explore the difference of BIAsp30 and BHI30 for treating glycemic excursion and hypoglycemic events in type 2 diabetes mellitus（T2DM）.Methods The T2DM patients poorly controlled by oral hypoglycemic drugs were randomly divided into the BIAsp30 group and the BHI30 group.After achieving the standard of fingertip capillary blood glucose,the glycemic excursion and hypoglycemic events were measured by continuous glucose monitoring system（CGMS） for 3 d.Results The mean value,maximum value and minimum value of fingertip capillary blood glucose had no statistical difference between the two groups（P0.05）,but glycemic excursion and hypoglycemic events in the BIAsp30 group were significantly decreased compared with the BHI30 group during monitoring by continuous glucose monitoring system（CGMS）,showing statistical difference between the two groups（P0.05）.Conclusion Although the glycemic control capacity of BIAsp30 is equivalent to BHI30 in T2DM,BIAsp30 had much less glycemic excursion and hypoglycemic events.So BIAsp 30 in treatment of T2DM still has certain advantages,which is worthy of being widely popularized.